Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Elanix Biotechnologies AG    ELN   DE000A0WMJQ4

ELANIX BIOTECHNOLOGIES AG

(ELN)
  Report  
SummaryQuotesNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/13/2019 | 11:50pm BST

DGAP-Ad-hoc: Elanix Biotechnologies AG / Key word(s): Legal Matter/Miscellaneous
Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda

14-Feb-2019 / 00:47 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Elanix Biotechnologies AG: Criminal charges to be filed against former CEO Tomas J. Svoboda

Berlin, February 14, 2019 - Previous ad hoc announcement (February 11, 2019) of Elanix Biotechnologies AG ("Company") mentioned mismanagement during the tenure of former CEO Tomas J. Svoboda. After further detailed examination of the situation of the company by current management and legal team, evidence was gathered to constitute criminal charges to be filed against former CEO Tomas J. Svoboda. The full charges will be filed without delay against Mr. Svoboda on the suspicion of several crimes, amongst others breach of trust and balance sheet manipulation. It is expected that the misconduct will lead or already led to considerable extraordinary expenses. Further and detailed information regarding the extent of the damage done to the company will be independently confirmed.

Lee Ann Laurent-Applegate
CEO

Contacts

Elanix Biotechnologies AG
Lee Ann Laurent-Applegate
Tel: +41 (0)22 363 66 40
investor.relations@elanix-bt.com

About Elanix

Elanix develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2012 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented human progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing.

Forward-looking statements

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.


14-Feb-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Elanix Biotechnologies AG
Stadthausbrücke 1-3
20355 Hamburg
Germany
Phone: +41 22 363 66 40
Fax: +41 22 363 66 41
E-mail: info@elanix-bt.com
Internet: www.elanixbiotechnologies.com
ISIN: DE000A0WMJQ4
WKN: A0WMJQ
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf

 
End of Announcement DGAP News Service

775779  14-Feb-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=775779&application_name=news&site_id=zonebourse

© EQS 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELANIX BIOTECHNOLOGIES AG
08/19ELANIX BIOTECHNOLOGIES AG : Preliminary announcement of the publication of finan..
EQ
07/26ELANIX BIOTECHNOLOGIES AG : Release according to Article 40, Section 1 of the Wp..
EQ
07/22ELANIX BIOTECHNOLOGIES AG : Release according to Article 40, Section 1 of the Wp..
EQ
06/25ELANIX BIOTECHNOLOGIES AG : Correction of a release from 20/06/2019 according to..
EQ
06/20ELANIX BIOTECHNOLOGIES AG : Release according to Article 40, Section 1 of the Wp..
EQ
05/13ELANIX BIOTECHNOLOGIES AG : Criminal charges have been filed against the former ..
EQ
04/1818-04-2019ELANIX BIOTECHNOLOGIES AG : Nomination of the chairman of the supervis..
PU
04/18ELANIX BIOTECHNOLOGIES AG : Nomination of the chairman of the supervisory board,..
EQ
03/27ELANIX BIOTECHNOLOGIES AG : Correction of 2015 Financial Statements - Release ac..
EQ
02/14ELANIX BIOTECHNOLOGIES AG : Resignation in Supervisory Board
EQ
More news
Financials (EUR)
Sales 2018 -
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 -
Capi. / Sales2018 -
Capi. / Sales2019 -
Capitalization 10,9 M
Chart ELANIX BIOTECHNOLOGIES AG
Duration : Period :
Elanix Biotechnologies AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 1,35  €
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Tomas J. Svoboda Chief Executive Officer
Jürgen Ferdinand Kullmann Chairman-Supervisory Board
Egon Minar Chief Operating & Financial Officer
Abigael de Buys Roessingh Member-Supervisory Board
Marc Voigt Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
ELANIX BIOTECHNOLOGIES AG-18.21%12
IQVIA HOLDINGS INC34.91%30 701
LONZA GROUP36.75%26 363
INCYTE CORPORATION32.91%18 177
CELLTRION, INC.--.--%16 143
EXACT SCIENCES CORPORATION89.89%15 300